AACR IMMUNO-ONCOLOGY (AACR IO)

DISCOVERY AND INNOVATION IN CANCER IMMUNOLOGY: REVOLUTIONIZING TREATMENT THROUGH IMMUNOTHERAPY

February 18–21, 2026 | Los Angeles, CA

AACR American Association for Cancer Research

Current as of February 9, 2026

Poster Session A (To be presented Wednesday, February 18, 7:30-10pm PT)

LB-A001 Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial. Aman Chauhan. Department of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

LB-A002 Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-L1-positive head and neck squamous cell carcinoma. Dave Drone. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.

LB-A003 Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial. Tim Remus. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.

LB-A004 DAREON-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus chemotherapy in patients with DLL3-positive neuroendocrine carcinomas. Aman Chauhan. Department of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

LB-A005 DAREON-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). Ticiana Leal. Winship Cancer Institute, Emory University Hospital, Department of Hematology and Medical Oncology, Atlanta, GA, United States.

LB-A006 Impact of pharmacokinetic profiles on the in vivoantitumor efficacy of EHMT2 inhibitors combined with immune checkpoint blockade. Unju Lee. Asan Preclinical Evaluation center for cancer therapeutiX, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Rep

LB-A007 Non-viral site-directed hYP218 CAR T cells for mesothelin-expressing solid tumors. Sameer Mir. NIH, Bethesda, Maryland 20892, USA., Bethesda, MD, United States.

LB-A008 Reversing immune checkpoint inhibitor resistance rherapy in advanced thyroid cancer. Joah Lee. University of California Los Angeles (UCLA), Los Angeles, CA, United States.

LB-A009 Neutrophils Drive Cancer Initiation in BRCA-Carriers via NF-κB Epigenetic Reprogramming of Luminal Progenitors into Aberrant Basal-Like Cells. Camilla Paleari. Institute of Oncology Research, Bellinzona, Switzerland.

LB-A010 Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced (adv) melanoma. Gino In. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

LB-A011 S100A9-releasing neutrophils promote breast cancer susceptibility in BRCA carriers. Hannah Dewhurst. Institute of Oncology Research (IOR), Bellinzona, Switzerland.

LB-A013 Tuning TCR immunotherapy targeting prostatic acid phosphatase via catch bond modifications for advanced prostate cancer. Zhiyuan Mao. University of California, Los Angeles, Los Angeles, CA, United States.

Poster Session B (To be presented Thursday, February 19, 12:15-3:15pm PT)

LB-B001 Recognition of senescent breast tumor antigen by CD4+ T cells causes IFNγ release leading to target gene expression. Calvin Adam. Tulane University School of Medicine, New Orleans, LA, United States.

LB-B002 A phase 1 trial of the oncolytic virus SVV-001 with Nivolumab and Ipilimumab in patients with high gradeNeuroendocrine Neoplasms Aman Chauhan. University of Southern California, San Francisco, CA, United States.

LB-B003 Exploiting lymphangiogenesis to boost anti-tumor T cell responses in B cell lymphoma. Emily(Qinyue) Liu. Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, United States.

LB-B004 CD8+Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor of Response to Neoadjuvant CadonilimabPlus Chemotherapy in Advanced Ovarian Cancerfrom the Phase II CANECT Trial. Jie Tang. Hunan Cancer Hospital, Changsha, China.

LB-B005 No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404. Megan Othus. Fred Hutchinson Cancer Center, Seattle, WA, United States.

LB-B006 A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis. Oliver Davidorf. Sarcoma Oncology Research Center, Santa Monica, CA, United States.

LB-B007 Systematic identification of noncanonical neoantigens from the dark genome in CEDAR using PEPMatch. Ibel Carri. La Jolla Institute for Immunology, La Jolla, CA, United States.

LB-B008 cDC expansion and CD40 activation after immunogenic chemotherapy shift the breast tumor microenvironment toward functional T cell immunity and IL-12-dependent tumor control. Sangeetha Reddy. University of Texas Southwestern Medical Center, Dallas, TX, United States.

LB-B009 Design and immunogenicity of sequential cancer vaccination targeting shared tumor-associated antigens and personalized neoantigens in a single patient with uterine leiomyosarcoma. Mansi Saxena. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

LB-B010 Model-informed discovery and optimization of dose, regimen, and route for a binding-protein-resistant cytokine receptor agonist for oncology . Iman Samiee. Gilead, Foster City, CA, United States.

LB-B011 DN64-CAR-V: AN OFF-THE-SHELF CYTOCIDAL CHIMERIC (tARGETED) AMPHOTROPIC RNA VECTOR FOR SELECTIVELY MODIFYING THE TUMOR MICROENVIRONMENT IN IL-6 DRIVEN SARCOMAS (NCT04091295). Piya Mann. University of Southern California, Los Angeles, CA, United States.

LB-B012 Signals from the tumor immune microenvironment induce a potent immune modulatory gene expression program in senescent breast tumor cells. Raegan Kvadas. Tulane University, New Orleans, LA, United States.

LB-B013 Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma. Fahad Kiani. CrisPRO.ai, Brooklyn, United States.

Poster Session C (To be presented Friday, February 20, 12:15-3:15pm PT)

LB-C001 Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma: Updated Results with Over Two Years Median Follow Up. Sophie Carlson. UCLA, Los Angeles, CA, United States.

LB-C004 Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: the phase II NIBIT-ML1 study. Anna Maria Di Giacomo. University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.

LB-C005 RedTail: A next-generation systemic platform for tumor-specific delivery of bites and immune activation. Duong Nguyen. Calidi Biotherapurtics, San Diego, CA, United States.

LB-C006 Scalable TCR synthesis and screening enable antigen reactivity mapping. Stephanie Gaglione. Gladstone Institutes, San Francisco, CA, United States.

LB-C007 Enhancing immune interactions in tumor with pepinemab SEMA4D blocking antibody. Elizabeth Evans. Vaccinex, Rochester, NY, United States.

LB-C008 Replication stress coupled to cGAS–STING activation defines an innate immune–inflamed transcriptional state in head and neck squamous cell carcinoma that Is enriched for HPV-positive disease. Harold Nathan Tan. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

LB-C009 Tumor methylation subtypes predict the clinical outcome to immunotherapy in pleural mesothelioma patients from the NIBIT-EPI-MESO study. Luana Calabrò. Department of Translational Medicine, University of Ferrara; Division of Medical Oncology, Department of Oncology, University Hospital of Ferrara, Ferrara, Italy.

LB-C010 Flare: A clinical stage platform designed to overcome challenges of the tumor microenvironment and universally target tumors of epithelial origin. Lex Johnson. Dispatch Bio, Philadelphia, PA, United States.

LB-C011 Using Organoids and Tumor Infiltrating Lymphocytes to Elucidate the ”Dark Matter” of Human Tumor Antigens. Ken-ichi Hanada. Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

LB-C012 Immune-Like Circulating Tumor Cells and Large Extracellular Vesicles in Metastatic Breast Cancer. Stephanie Shishido. USC, Los Angeles, CA, United States.